Study type: In vivo/preclinical · Status: Verified against declared source

Subclinical lipopolysaccharide from Salmonella Enteritidis induces neuroactive chemical sequence dysregulation in the spinal cord and the dorsal root ganglia.

BMC neuroscience · 2019

Study scale: There is a growing body of evidence that inflammatory triggers such as lipopolysaccharide (LPS) may be involved in the neurodegenerative processes and the sensory pathways connected with them [13].

Abstract only: Open source record

Product or molecular entity relationships

  • VIP: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

After a two-week adaptive period, the clinically healthy pigs were randomly divided into two groups (5 pigs in each group): a control group (Con, n = 5) and an experimental group (LPS, n = 5) and subjected to premedication, according to the method previously described by Mikołajczyk [92] with intramuscular injection of atropine (Atropinum Sulfuricum Polfa Warszawa S.A., Poland, 0.035 mg/kg b.w.), ketamine (Bioketan, Vetoquinol Biowet Sp.

Scale or participants

There is a growing body of evidence that inflammatory triggers such as lipopolysaccharide (LPS) may be involved in the neurodegenerative processes and the sensory pathways connected with them [13].

Key findings

Despite increasing evidence that lipopolysaccharide (LPS) affects the biological active substances of dorsal root ganglia (DRG) we have limited knowledge of the influence of a single low dose of LPS, which does not result in any clinical symptoms of disease (subclinical LPS) on neuropeptides connected with the sensory pathway.

Limitations and uncertainty

Moreover, the presence of LPS from pathogens such as Salmonella spp.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.